Market closed
Harvard Bioscience/HBIO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Harvard Bioscience
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
Ticker
HBIO
Sector
Trading on
Industry
Life Sciences Tools & Services
Headquarters
Employees
404
Website
HBIO Metrics
BasicAdvanced
$110M
Market cap
-
P/E ratio
-$0.25
EPS
1.31
Beta
-
Dividend rate
Price and volume
Market cap
$110M
Beta
1.31
52-week high
$5.56
52-week low
$2.32
Average daily volume
115K
Financial strength
Current ratio
2.053
Quick ratio
0.731
Long term debt to equity
54.535
Total debt to equity
61.64
Interest coverage (TTM)
-1.11%
Management effectiveness
Return on assets (TTM)
-1.62%
Return on equity (TTM)
-14.97%
Valuation
Price to revenue (TTM)
1.077
Price to book
1.64
Price to tangible book (TTM)
-39.11
Price to free cash flow (TTM)
17.93
Growth
Revenue change (TTM)
-11.36%
Earnings per share change (TTM)
93.45%
3-year revenue growth (CAGR)
-3.12%
3-year earnings per share growth (CAGR)
52.41%
What the Analysts think about HBIO
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Harvard Bioscience stock.
HBIO Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
HBIO Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
HBIO News
AllArticlesVideos
Harvard Bioscience to Showcase Latest Solutions for Preclinical and Organoid Applications at Safety Pharmacology Society Annual Meeting
GlobeNewsWire·4 weeks ago
Harvard Bioscience, Inc. to Participate in the Sidoti Small Cap Virtual Conference
GlobeNewsWire·1 month ago
Harvard Bioscience, Inc. (HBIO) Q2 2024 Earnings Call Transcript
Seeking Alpha·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Harvard Bioscience stock?
Harvard Bioscience (HBIO) has a market cap of $110M as of October 13, 2024.
What is the P/E ratio for Harvard Bioscience stock?
The price to earnings (P/E) ratio for Harvard Bioscience (HBIO) stock is 0 as of October 13, 2024.
Does Harvard Bioscience stock pay dividends?
No, Harvard Bioscience (HBIO) stock does not pay dividends to its shareholders as of October 13, 2024.
When is the next Harvard Bioscience dividend payment date?
Harvard Bioscience (HBIO) stock does not pay dividends to its shareholders.
What is the beta indicator for Harvard Bioscience?
Harvard Bioscience (HBIO) has a beta rating of 1.31. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.